NEIL KUMAR - 16 Aug 2023 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
CEO and President, Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
16 Aug 2023
Net transactions value
-$2,984,584
Form type
4
Filing time
18 Aug 2023, 16:00:08 UTC
Previous filing
18 May 2023
Next filing
20 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise +102,250 +2.1% 4,915,447 16 Aug 2023 Direct F1
transaction BBIO Common Stock Tax liability $1,510,800 -50,698 -1% $29.80 4,864,749 16 Aug 2023 Direct F2
transaction BBIO Common Stock Sale $1,473,784 -51,552 -1.1% $28.59 4,813,197 17 Aug 2023 Direct F3
holding BBIO Common Stock 1,012,722 16 Aug 2023 See Footnote F4
holding BBIO Common Stock 995,686 16 Aug 2023 See Footnote F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Restricted Stock Units Options Exercise $0 -5,130 -25% $0.000000 15,388 16 Aug 2023 Common Stock 5,130 Direct F1, F6
transaction BBIO Restricted Stock Units Options Exercise $0 -2,394 -14% $0.000000 14,365 16 Aug 2023 Common Stock 2,394 Direct F1, F7
transaction BBIO Restricted Stock Units Options Exercise $0 -61,182 -33% $0.000000 122,364 16 Aug 2023 Common Stock 61,182 Direct F1, F8
transaction BBIO Restricted Stock Units Options Exercise $0 -33,544 -6.7% $0.000000 469,616 16 Aug 2023 Common Stock 33,544 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 102,250 shares of Common Stock underlying the Reporting Person's RSUs.
F3 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2022.
F4 The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F5 The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F6 The RSUs vest with respect to 1/16th of the underlying shares on August 16, 2020. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F7 The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F8 The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F9 The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.